The Zacks Analyst Blog Highlights: Covidien, General Electrical, Becton, Dickinson and Company, Johnson and Johnson and CR Bard - Press Releases


Shutterstock photo

For Immediate Release

Chicago, IL - May 14, 2012 - announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Covidien ( COV ), General Electrical ( GE ), Becton, Dickinson and Company ( BDX ), Johnson and Johnson ( JNJ ) and CR Bard Inc . ( BCR ).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Friday's Analyst Blog:

Covidien Teams Up with GE Health


Large-cap medical technology company, Covidien ( COV ) recently announced a five-year worldwide collaboration with GE Healthcare, a division of General Electrical ( GE ). The collaboration will allow GE Healthcare, a market leader in biomedical devices and services, to include the measurement technology used by Covidien in its patient monitoring systems.

GE Healthcare asserts that the collaboration will improve the standard of patient monitoring and safety. The alliance also manifests an undertaking by GE Healthcare to maintain an extensive patient monitoring system that is easily accessible to clinicians and healthcare administrators.

Following this collaboration, GE's monitoring systems including CARESAPE Monitor B850 and CARESCAPE Monitor B650 will have easy access to the measurement technologies of Covidien, enhancing the clinical information available to physicians.

On the other hand, the collaboration will enhance the technology portfolio of Covidien associated with patient monitoring. The Nellcor pulse oximetry with Oximac Technology, INVOS Cerebral/ Somatic Oximetry and BIS Brain Monitoring will get the maximum advantage.

The oximetry and monitoring products are a part of Medical Devices segment, the primary growth driver of Covidien. These products edged up by 4% year over year in the second quarter, reflecting double-digit growth in sale of monitors (Nellcor, INVOS, BIS). The alliance will leverage the sales growth of monitors, leading to an increase in market share of the oximetry and monitoring sub segment, which was reportedly flat during the first quarter.

GE Healthcare has industry experience of about 100 years in the development and production of healthcare devices and services.  The company will be able to assimilate clinical measurements and other patient health parameters at the point of care. It will thereby support accurate decision making after the alliance.

Also, Covidien management believes that the specialized measurement technology hitched with the patient monitors at GE Healthcare will ensure greater precision in patient care and safety.

Covidien is a leading developer, manufacturer and distributor of medical devices and services on a global scale.  Its business segments overlap with the business of its competitors such as Becton, Dickinson and Company ( BDX ), Johnson and Johnson ( JNJ ) and CR Bard Inc . ( BCR ) among others.

With a growth rate higher than its competitors, the stock currently retains a Zacks #2 Rank, which translates into a short-term Buy. However, we maintain a long-term Neutral recommendation on the stock.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: .

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at .

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

BARD C R INC (BCR): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
COVIDIEN PLC (COV): Free Stock Analysis Report
GENL ELECTRIC (GE): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing Stocks
Referenced Stocks: BCR , BDX , COV , GE , JNJ

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by